| Japanese |
|---|
| Title | 11C-N-メチルスピペロンの非プロラクチン産生下垂体腫瘍への応用 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 百瀬敏光*, 寺本明**, 西川潤一*, 井上優介*, 渡辺俊明*, 佐々木康人* |
|---|
| Authors(kana) | |
|---|
| Organization | *東京大学医学部放射線医学教室, **東京大学医学部脳神経外科学教室 |
|---|
| Journal | 核医学 |
|---|
| Volume | 30 |
|---|
| Number | 6 |
|---|
| Page | 627-635 |
|---|
| Year/Month | 1993/6 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」 11C-NMSPとPETを用いて非プロラクチン産生下垂体腫瘍8例(non-functioning 4例, GH-secreting 2例, ACTH secreting 1例, TSH-secreting 1例)のドーパミンD2受容体への結合能を評価した. 8例全例で腫瘍部への集積を認めた. 3コンパートメントを想定し, 小脳への集積を入力関数として算出した等価時間に対する腫瘍部/小脳比, 線条体/小脳比, 正常下垂体/小脳比の傾きから, 各部位での11C-NMSPとD2受容体との結合速度定数αを算出した. また, 11C-NMSP投与75分から80分における各部位における対小脳比を算出した. α値は対小脳比と良好な直線的相関を示した. 腫瘍部のα値は, すべての症例で正常下垂体より高かったが, 1例を除き線条体の6〜7割程度であった. 1例では線条体の2倍であった. 3例でブロモクリプチン投与により腫瘍部のα値は低下したが, 線条体では不変であった. 非プロラクチン産生腫瘍においてもD2受容体が少なからず存在することが示唆された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 11C-N-methylspiperone, Positron emission tomography, Dopamine D2 receptor, Pituitary adenoma, Bromocriptine |
|---|
| English |
|---|
| Title | Clinical Application of 11C-NMSP to the Patients with Pituitary Adenoma other than Prolactinoma |
|---|
| Subtitle | |
|---|
| Authors | Toshimitsu MOMOSE*, Akira TERAMOTO**, Junichi NISHIKAWA*, Yusuke INOUE*, Toshiaki WATANABE*, Yasuhito SASAKI* |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, **Department of Neurosurgery, Faculty of Medicine, University of Tokyo |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 30 |
|---|
| Number | 6 |
|---|
| Page | 627-635 |
|---|
| Year/Month | 1993/6 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] The existence of dopamine D2 receptors in the pituitary adenoma is an important factor for bromocriptine therapy. In order to evaluate the D2 receptors in the pituitary adenoma, 11C-N-methylspiperone (NMSP) and positron emission tomography was performed in a variety of pituitary adenomas other than prolactinoma. Eight patients with pituitary adenoma including four non-functioning adenomas, two growth hormone (GH) secreting adenomas, one ACTH secreting adenoma and one TSH secreting adenoma and ten normal healthy volunteers were examined. 740 MBq of 11C-NMSP was injected and dynamic scan was performed from the time of injection to 80 min postinjection. The time dependent regional radioactivity in the striatum (st) and in the tumor tissue (tm) was measured and the binding rate, α, was calculated according to the following equation: Cst, tm/Ccbl=α×∫t0 Ccbl dt/Ccbl+1. The ratio of total radioactivity in the striatum or tumor over total activity in the cerebellum was plotted versus "normalized time", which was obtained by dividing integrated cerebellar radioactivity by actual cerebellar radioactivity for each timepoint. In three patients with pituitary adenoma, two scans were performed before and three hours after oral intake of 2.5 mg of bromocriptine. The α values for pituitary adenoma and normal striatum were 0.031+-0.023 (0.017-0.088) and 0.042+-0.006 (0.034-0.049), respectively. Bromocriptine reduced α value to various degree in pituitary adenoma (13-56%) but not in striatum (-3.7-3.3%). Our data suggests that in some of pituitary adenoma other than prolactinoma, dopamine D2 receptors existed but that nonspecific binding also contributed to the radioactivity in the tumor tissue. And it also supports the idea that in pituitary adenoma, bromocriptine directly combines with D2 receptor but in striatum, it might affect receptors other than D2 receptor itself. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 11C-N-methylspiperone, Positron emission tomography, Dopamine D2 receptor, Pituitary adenoma, Bromocriptine |
|---|